• CoronaCoronavirus (COVID-19) Resources

    In an effort to support our members with the most updated information on COVID-19 we developed this resource page to easily access current CDC information and other resources to assist you professionally and personally.

    We will continue to update this page with more information as it becomes available and welcome your input as we navigate through this situation. As health care professionals it is our job to educate our patients and families on prevention and the what to do if someone is symptomatic.

    View resources


  • AwardCall for Excellence Award Nominations

    The awards are: Emerging Chapter Award, Established Chapter Excellence Award, Special Interest Group Excellence Award, Excellence in Clinical Practice Award, Excellence in Community Service Award, Excellence in Education Award, Excellence in Leadership Award, and Excellence in Research Award.

    The nominations are tallied in July and the winners are announced every year during the Awards Celebration at the GAPNA Annual Conference.

    Now is the time to nominate a colleague or yourself - DEADLINE is June 1, 2020.

    Get started... nominate today!

  • Meet the Candidates for the 2020-2021 BOD!
    Voting begins May 4 - 29, 2020!

    Please take a moment to read about this year’s candidates and why they feel they should be chosen for the position noted.


Little Difference in Effectiveness of Drugs to Prevent Episodic Migraine in Adults

Migraine headaches affect 17 percent of women and 6 percent of men in the United States and fall into two classes: episodic migraines, defined as lasting less than 15 days per month, and chronic migraines that last at least 15 days per month for at least 3 months.

Even episodic migraines can cause serious lifestyle limitations, requiring preventive medication. All four drugs approved by the U.S. Food and Drug Administration for prevention of adult episodic migraine (the anti-epileptics, divalproex and topiramate, and the beta-blockers, timolol and propranolol) were found effective in a review of studies on the medications.

These drugs were better than placebo in reducing monthly migraine frequency by at least 50% in 200-400 patients per 1,000 treated, according to a the review of 215 randomized controlled trials and 76 nonrandomized studies. However, none of the approved drugs was significantly more beneficial than the others.

More details are in Shamiliyan et al. (2013). Preventive pharmacologic treatments for episodic migraine in adults. Journal of General Internal Medicine, 28(9), 1225-1237.

Related Topic 1: 

GAPNA Newsletter Issue: